breast cancer
Conditions
Interventions
Experimental:Docetaxel, epirubicin, lobaplatin
control group:Docetaxel, epirubicin
Sponsors
Southwest Hospital, Third Military Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 69 Years
Inclusion criteria
Inclusion criteria: 1) Females aged 18-70 years; 2) The patients with stage I to III breast cancer who undergo no surgery, the diagnosis should be histopathologically confirmed by core needle biopsy before treatment and the tumor can be surgically removed. IHC assay shows ER (-), PR (-), HER -2/neu (-); 3) The tumor size can be measured; 4) before chemotherapy, abdominal B-type ultrasound, chest X-ray and bone scan of the whole body are conducted to exclude the patients with distal metastasis, fine needle aspiration for enlarged lymph node to clarify whether exists the tumor metastasis. The patients show no other malignant tumors; 5) Compliancy; 6) ECOG score: 0 or 1; 7) All the patients voluntarily participate in the study and signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1) In pregnancy or lactation; 2) the patients with severe heart, liver, kidney, endocrine system diseases, and the expected survival from these diseases shorter than 2 years; 3) being allergic to the medication; 4) Karnofsky score less than 60; 5) the patients cannot be treated and rechecked on time for some reason; 6) Other patients not suitable for this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pCR; | — |
Countries
China
Contacts
Public ContactZhang Yi
Outcome results
None listed